Depakote Should NOT Be Used to Treat Hypersexuality in This Patient
Valproate (Depakote) is ineffective for managing hypersexuality in dementia and carries significant risks in elderly patients, particularly increased somnolence, dehydration, and serious adverse events. 1, 2
Evidence Against Valproate Use
Lack of Efficacy for Behavioral Symptoms
The highest quality evidence demonstrates that valproate preparations are probably ineffective for treating agitation and behavioral disturbances in dementia. A Cochrane systematic review of 5 randomized controlled trials (430 participants) found no benefit on agitation measures including the BPRS agitation factor (MD -0.67,95% CI -1.49 to 0.15) and Cohen-Mansfield Agitation Index over 6 weeks 2. While this evidence specifically addresses agitation rather than hypersexuality, it establishes that valproate lacks efficacy for neuropsychiatric symptoms of dementia broadly.
Significant Safety Concerns in Elderly Dementia Patients
The FDA label for Depakote specifically warns about somnolence in elderly patients with dementia 1. In a double-blind trial of elderly dementia patients (mean age 83 years), valproate caused:
- Significantly higher somnolence compared to placebo
- Higher rates of dehydration
- Reduced nutritional intake and weight loss
- Higher discontinuation rates
The Cochrane review found valproate-treated patients experienced higher rates of adverse effects (OR 2.02,95% CI 1.30 to 3.14) and possibly more serious adverse events (OR 4.77,95% CI 1.00 to 22.74), including sedation, gastrointestinal symptoms, and urinary tract infections 2.
Drug Interaction Concerns
Adding valproate to this patient's current olanzapine 10 mg daily regimen would reduce olanzapine plasma concentrations by approximately 24-26% 3, 4, 5. This pharmacokinetic interaction occurs through presystemic metabolism induction and could compromise the effectiveness of the olanzapine already prescribed.
Recommended Approach for Hypersexuality in Dementia
First-Line: Non-Pharmacological Interventions
Current guidelines emphasize that psychotropic medications should only be used after significant efforts with behavioral and environmental modifications 6, 7. For hypersexuality specifically:
- Redirect the patient to alternative meaningful activities
- Modify environmental triggers
- Establish structured routines
- Ensure privacy and dignity
- Educate caregivers that behaviors are not intentional
Pharmacological Options If Needed
If non-pharmacological approaches fail and the behavior poses significant risk or distress, SSRIs (particularly citalopram) have case report evidence for reducing hypersexual behavior in Alzheimer's disease 8. A case report demonstrated improvement in compulsive sexual behavior after 60 days of citalopram treatment in a 54-year-old male with AD.
Optimize Current Medication
Before adding any new agent, consider whether the current olanzapine dose is optimized. The patient is already on 10 mg daily, which is a moderate dose. However, guidelines recommend using the minimum effective dose and regularly reassessing need 7.
Critical Caveats
- Hypersexuality is not an FDA-approved indication for any psychotropic medication in dementia
- The evidence base for treating hypersexuality specifically is extremely limited
- Any medication use requires careful risk-benefit discussion with the patient (if feasible) and surrogate decision-makers 7
- Close monitoring for adverse effects is essential, particularly somnolence, falls, and metabolic effects in this 72-year-old patient
- Consider whether the behavior truly requires pharmacological intervention or if it can be managed through environmental and behavioral strategies alone
In summary: Do not use Depakote for this indication. Focus on non-pharmacological interventions first, and if medication is absolutely necessary after behavioral approaches fail, consider an SSRI like citalopram rather than valproate.